Tripotassium dicitrato-bismuthate tablets v liquid in the treatment of duodenal ulcers.

Abstract	Thirty-five patients with duodenal ulcers were treated with tripotassium dicitrato-bismuthate (TDB) in a double-blind, double-dummy endoscopically controlled trial. Healing rates were comparable in patients treated with either tablet or liquid, 74% and 72% at four weeks and 89% in both groups at eight weeks. It is concluded that the tablet formulation of TDB is as effective as the liquid in the treatment of acute duodenal ulceration.
Authors	M Lane, S Lee, C Tasman-Jones, G Nicholson
Journal	The New Zealand medical journal (N Z Med J) Vol. 98 Issue 775 Pg. 191-2 (Mar 27 1985) ISSN: 0028-8446 [Print] New Zealand
PMID	3885084 (Publication Type: Clinical Trial, Comparative Study, Controlled Clinical Trial, Journal Article)
Chemical References	Anti-Ulcer Agents Organometallic Compounds Solutions Tablets bismuth tripotassium dicitrate Bismuth
Topics	Adult Aged Anti-Ulcer Agents (administration & dosage) Bismuth (administration & dosage) Clinical Trials as Topic Double-Blind Method Duodenal Ulcer (drug therapy) Female Humans Male Middle Aged Organometallic Compounds Solutions Tablets

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!